Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022

SELL
$1.3 - $3.17 $18,073 - $44,072
-13,903 Reduced 38.07%
22,620 $33,000
Q3 2021

Nov 12, 2021

BUY
$2.91 - $4.5 $378 - $585
130 Added 0.36%
36,523 $109,000
Q2 2021

Aug 11, 2021

SELL
$4.15 - $6.3 $286,955 - $435,619
-69,146 Reduced 65.52%
36,393 $168,000
Q1 2021

May 13, 2021

SELL
$5.51 - $9.42 $53,171 - $90,903
-9,650 Reduced 8.38%
105,539 $633,000
Q4 2020

Feb 09, 2021

BUY
$3.42 - $6.36 $94,901 - $176,483
27,749 Added 31.73%
115,189 $603,000
Q3 2020

Nov 12, 2020

BUY
$2.94 - $12.43 $1,284 - $5,431
437 Added 0.5%
87,440 $302,000
Q2 2020

Aug 12, 2020

BUY
$5.28 - $9.67 $35,856 - $65,668
6,791 Added 8.47%
87,003 $755,000
Q1 2020

May 06, 2020

BUY
$5.0 - $7.6 $17,250 - $26,220
3,450 Added 4.49%
80,212 $465,000
Q4 2019

Feb 14, 2020

BUY
$5.99 - $8.38 $65,943 - $92,255
11,009 Added 16.74%
76,762 $553,000
Q3 2019

Nov 07, 2019

SELL
$5.62 - $9.63 $21,148 - $36,237
-3,763 Reduced 5.41%
65,753 $401,000
Q2 2019

Aug 12, 2019

BUY
$7.59 - $10.21 $46,390 - $62,403
6,112 Added 9.64%
69,516 $660,000
Q1 2019

May 14, 2019

BUY
$7.65 - $16.66 $36,597 - $79,701
4,784 Added 8.16%
63,404 $514,000
Q4 2018

Feb 11, 2019

BUY
$10.76 - $17.25 $461,765 - $740,283
42,915 Added 273.26%
58,620 $953,000
Q3 2018

Nov 09, 2018

BUY
$14.34 - $22.97 $64,988 - $104,100
4,532 Added 40.56%
15,705 $0
Q2 2018

Aug 06, 2018

BUY
$12.76 - $16.94 $142,567 - $189,270
11,173 New
11,173 $168,000

Others Institutions Holding UBX

# of Institutions
1
Shares Held
4.41M
Call Options Held
0
Put Options Held
0

About Unity Biotechnology, Inc.


  • Ticker UBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,036,200
  • Market Cap $14M
  • Description
  • Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...
More about UBX
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.